The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a Diabetic Macular Oedema (DMO) treatment pathway attached below for information. 

The Prescribing Clinical Network recommends the use of Fluocinolone acetonide intravitreal implant for the treatment of DMO in patients who have failed to respond to prior therapy and have an intraocular lens. in line with NICE TA 301. Prior therapy is to include both laser photocoagulation and anti VEGF therapies.

Fluocinolone acetonide intravitreal implant should be used only by specialists and as such is considered as RED on the traffic light system.

Fluocinolone acetonide intravitreal implant is excluded from the National Tariff when administered for its licensed indication. It should only be used within a hospital setting by suitably trained specialists, and will not be transferred to primary care. Providers should apply for funding using the Blueteq system.